

Multimorbidity burden in an HIV population aged over 50 in South-East England

L Mortimer¹, J Wright¹ and T Levett¹

¹Brighton and Sussex Medical School, Brighton UK

Email: l.mortimer@doctors.org.uk

Background

- The success of antiretroviral therapy (ART) is a driver of ageing in people living with HIV (PLWH).
- PLWH face significant co-morbidities as they age and have higher multimorbidity (MM) prevalence rates compared to the general population ^{1,2}. This raises concerns over polypharmacy and drug-drug interactions, increased use of healthcare resources and negative impact on quality of life.
- Different hypotheses exist for why greater MM occurs in PLWH, notably chronic inflammation, premature immunosenescence and ART toxicity alongside a greater burden of behavioural risk factors ^{3,4}. Many associations with MM are reported including both HIV factors and traditional risk factors.
- This study aimed to determine the comorbidities present, MM prevalence and associations with MM amongst PLWH age >50 in South East England.


Methods

- 253 PLWH age >50 were recruited from HIV clinics across Sussex between October 2014-2015.
- Multimorbidity was defined as the presence of ≥2 non-HIV defining conditions.
- Participants self-reported comorbidities via a comprehensive questionnaire (checked against medication/laboratory results).
- Electronic laboratory records were used to obtain relevant HIV and ART history.
- Frailty status was assessed using modified Fried's frailty phenotype ⁵. This includes five parameters: weight loss, exhaustion, low physical activity, slow walk speed and weak grip strength. Sum ≥ 3 were deemed frail, <3 non-frail.

Results

- Population:** Median age 59.6 years, 90.9% male, 91.3% Caucasian. Mean duration of HIV infection was 14.9 years (SD ±8.1), 97.6% were on ART and current CD4 count was 656 (SD± 281).
- Co-morbidities:** Many chronic conditions were present, the most commonly occurring comorbidities (frequency >10%) are shown in figure 1. In addition, 30% of the cohort had non-ART polypharmacy (≥5 drugs/day).

Figure 1: Prevalence of selected comorbidities




*Chronic pain = patients reported daily pain due to a range of painful conditions **CKD = chronic kidney disease... ***MSK (musculoskeletal) diagnosis = diseases such as gout, plantar fasciitis, spinal pathologies and fibromyalgia.

Results (continued)

- Multimorbidity:** Present in 62.9% and rose with age (figure 2). Those with MM were older than those without (median age 60.5 vs 58.6, p=0.023).

Figure 2: Percentage comorbidity burden by age strata



- Associations:** MM was associated with non-HIV factors including gender, frailty and current symptoms of mood disorder; furthermore MM was associated with greater markers of immunosuppression (but not current CD4 count). (See table 1 and 2).

Table 1: Non-HIV associations with MM

Category	No MM (n=94)	Multimorbidity (n=159)	P-value
Male gender	81 (86.2%)	149 (93.7%)	P=0.044
Frailty present	5 (5.3%)	43 (27.0%)	P<0.001
History of depression	12 (12.8%)	60 (37.7%)	P<0.001
Non-ART polypharmacy present	2 (2.1%)	74 (46.5%)	P<0.001
Current statin use	16 (17.0%)	92 (57.9%)	P<0.001
Current smoker	19 (20.2%)	34 (21.4%)	P=0.390
Further education	57 (60.6%)	89 (56.0%)	P=0.468

Table 2: HIV associations with MM

Category	No MM (n=94)	Multimorbidity (n=159)	P-value
HIV duration (mean years)	12.5 (±8.1)	16.3 (±7.8)	P<0.001^a
Current CD4 ≥350 (cells/mm ³)	88 (93.6%)	137 (86.2%)	P=0.183
Nadir CD4 <350 (cells/mm ³)	78 (83.9%)	143 (92.3%)	P=0.040
AIDS diagnosis	22 (23.4%)	56 (35.2%)	P=0.049

^a P value generated by Mann-Whitney U-test, rest of statistical analysis used Chi squared test.

Conclusions

- In this ART experienced cohort, there were high levels of multimorbidity with age, gender, frailty status and HIV-factors associated with MM.
- The study results support previous findings of high MM prevalence and is towards the upper end of reported MM in PLWH (10.8-73.7%); but is similar to other older cohorts studied ^{2, 6-7}.
- The results suggest clinicians will need to adopt a patient centred approach towards PLWH, rather than single organ management. Both preventative approaches and education alongside proactive management to identify comorbidities should be adopted in order to improve patient outcomes.
- Studies of MM in PLWH highlight the importance of developing clear guidance for managing multiple comorbidities/polypharmacy for PLWH. Ongoing research to explore the pathophysiological mechanisms underlying MM development may allow improved patient management in the future.